share_log

Solid Earnings May Not Tell The Whole Story For Intco Medical Technology (SZSE:300677)

Solid Earnings May Not Tell The Whole Story For Intco Medical Technology (SZSE:300677)

英科医疗(SZSE:300677)的稳定收益可能不是全部的故事。
Simply Wall St ·  09/04 21:22

The recent earnings posted by Intco Medical Technology Co., Ltd. (SZSE:300677) were solid, but the stock didn't move as much as we expected. We believe that shareholders have noticed some concerning factors beyond the statutory profit numbers.

英科医疗技术股份有限公司(深圳证券交易所:300677)最近发布的收益表现不错,但股价的波动没有我们预期的那么大。我们相信股东们已经注意到了一些令人担忧的因素,超出了法定盈利数字。

big
SZSE:300677 Earnings and Revenue History September 5th 2024
SZSE:300677收益和营收历史纪录,2024年9月5日

How Do Unusual Items Influence Profit?

非常规项目如何影响利润?

Importantly, our data indicates that Intco Medical Technology's profit received a boost of CN¥226m in unusual items, over the last year. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. We ran the numbers on most publicly listed companies worldwide, and it's very common for unusual items to be once-off in nature. Which is hardly surprising, given the name. We can see that Intco Medical Technology's positive unusual items were quite significant relative to its profit in the year to June 2024. As a result, we can surmise that the unusual items are making its statutory profit significantly stronger than it would otherwise be.

重要的是,我们的数据显示,英科医疗技术的利润在过去一年中由飞凡项利润增加了22600万人民币。虽然我们喜欢看到利润增长,但当飞凡项目做出重大贡献时,我们往往会更加谨慎。我们对全球大多数上市公司进行了数据分析,发现飞凡项目通常是一次性的。这一点并不令人意外,因为名字上就有提示。我们可以看到,与2024年6月的利润相比,英科医疗技术的正常飞凡项利润相对较大。因此,我们可以推测,飞凡项目使其法定利润显著强于否则的情况。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

这可能会让您想知道分析师对未来盈利能力的预测。幸运的是,您可以单击此处查看基于其估计的未来盈利能力的互动图表。

Our Take On Intco Medical Technology's Profit Performance

关于英科医疗技术的盈利表现我们的看法

As previously mentioned, Intco Medical Technology's large boost from unusual items won't be there indefinitely, so its statutory earnings are probably a poor guide to its underlying profitability. As a result, we think it may well be the case that Intco Medical Technology's underlying earnings power is lower than its statutory profit. But at least holders can take some solace from the 33% EPS growth in the last year. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. So while earnings quality is important, it's equally important to consider the risks facing Intco Medical Technology at this point in time. While conducting our analysis, we found that Intco Medical Technology has 1 warning sign and it would be unwise to ignore it.

如前所述,英科医疗因飞凡项目的大幅提升而导致的非常规收入不会无限期地存在,因此其法定收益可能并不是其潜在盈利能力的良好指标。 因此,我们认为英科医疗的潜在盈利能力可能低于其法定利润。 但至少股东们可以从去年33%的每股收益增长中稍稍得到些安慰。归根结底,如果您想要全面了解该公司,就必须考虑不仅仅是上述因素。 因此,虽然盈利质量很重要,但同样重要的是要考虑目前英科医疗面临的风险。 在我们的分析中,我们发现英科医疗存在1个警示信号,而忽视它是不明智的。

Today we've zoomed in on a single data point to better understand the nature of Intco Medical Technology's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.

今天,我们已经将注意力集中在一个单一数据点上,以更好地了解英科医疗利润的性质。 但是,如果你有能力专注于细枝末节,总是可以发现更多东西。 例如,许多人认为高净资产收益率是有利于企业经济的指标,而另一些人则喜欢“追随资金”并寻找内部人员正在买入的股票。因此,您可能希望查看拥有高净资产收益率的公司集合或持有高内部股权的股票清单。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发